Sharp, Octavian

Sharp, Octavian was paid $116K by Medicaid between Jan 2018 and Aug 2020, across 21 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 37% of everything it billed.

33Billing provider infoSHARP, OCTAVIAN
MEMPHIS, TN 38116

33aNPI1184938201assigned 07/30/2010

33bProvider typeFamily Nurse Practitioner

28Total paid$116K

24GClaims8,283

24DCodes billed21

24AFirst – last monthJan 2018 – Aug 2020

Compared with peers

Next to other Family Nurse Practitioner providers in Tennessee

Rank by total paid#140 of 687

Median peer was paid$15K

This provider vs. median8.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,819	$94K
2019	2,418	$12K
2020	1,046	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	37%	3,978	2,939	$43K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	14%	467	413	$17K
96120		11%	702	577	$13K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	9.8%	216	178	$11K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	7.1%	577	494	$8K
G0396	Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes	7.1%	698	575	$8K
96102		6.5%	473	361	$8K
96103		2.7%	248	219	$3K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.2%	19	18	$3K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.4%	255	220	$2K
99442		<1%	41	29	$482.37
80305		<1%	217	138	$215.63

9 more codes

81002		<1%	35	$13.08
81000		<1%	135	$12.09
G9578	Documentation of signed opioid treatment agreement at least once during opioid therapy	0%	16	$0.00
G9562	Patients who had a follow-up evaluation conducted at least every three months during opioid therapy	0%	16	$0.00
G8730	Pain assessment documented as positive using a standardized tool and a follow-up plan is documented	0%	16	$0.00
G9584	Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy	0%	16	$0.00
87641		0%	50	$0.00
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	0%	58	$0.00
87640		0%	50	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.